Meeting
2011 ASCO Annual Meeting
A phase I study of dovitinib in combination with capecitabine and oxaliplatin in upfront treatment of advanced colorectal and gastric cancer with a dose expansion cohort in advanced gastric cancer.
Authors
W. M. D. Tai
National Cancer Centre, Singapore, Singapore
W. M. D. Tai , W. S. Ooi , J. Y. Ngeow , N. Deng , H. Wang , C. K. Tham , H. Y. Lim , S. P. Choo , P. Tan , H. C. Toh , I. B. Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Esophageal, Gastric, or Small Bowel
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS174)
Abstract #
TPS174
Poster Bd #
45D
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.
First Author: Aparna Raj Parikh
Poster
2019 Gastrointestinal Cancers Symposium
NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.
First Author: T.R. Jeffry Evans
Poster
2018 ASCO Annual Meeting
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without systemic bevacizumab, for patients with advanced cancer and liver involvement.
First Author: Elena Fountzilas
Poster
2018 ASCO Annual Meeting
NuTide 302: A phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment.
First Author: Sarah Patricia Blagden